Fishman Jay A Ltd. MI lowered its position in Stryker Co. (NYSE:SYK) by 0.9% during the 3rd quarter, HoldingsChannel reports. The fund owned 112,760 shares of the medical technology company’s stock after selling 1,020 shares during the period. Stryker comprises about 4.6% of Fishman Jay A Ltd. MI’s investment portfolio, making the stock its 7th largest holding. Fishman Jay A Ltd. MI’s holdings in Stryker were worth $24,390,000 at the end of the most recent reporting period.
Several other institutional investors and hedge funds have also recently made changes to their positions in the company. Benjamin F. Edwards & Company Inc. increased its stake in Stryker by 10.2% in the 3rd quarter. Benjamin F. Edwards & Company Inc. now owns 15,332 shares of the medical technology company’s stock worth $3,316,000 after buying an additional 1,415 shares during the period. Benjamin Edwards Inc. grew its holdings in Stryker by 10.4% during the 3rd quarter. Benjamin Edwards Inc. now owns 617 shares of the medical technology company’s stock worth $133,000 after acquiring an additional 58 shares in the last quarter. Carillon Tower Advisers Inc. bought a new position in Stryker during the 3rd quarter worth about $2,639,000. Brasada Capital Management LP grew its holdings in Stryker by 3.0% during the 3rd quarter. Brasada Capital Management LP now owns 3,327 shares of the medical technology company’s stock worth $720,000 after acquiring an additional 97 shares in the last quarter. Finally, CNB Bank grew its holdings in Stryker by 18.0% during the 3rd quarter. CNB Bank now owns 813 shares of the medical technology company’s stock worth $176,000 after acquiring an additional 124 shares in the last quarter. 73.13% of the stock is currently owned by institutional investors and hedge funds.
In related news, CEO Kevin Lobo sold 19,286 shares of the stock in a transaction that occurred on Thursday, October 31st. The shares were sold at an average price of $215.71, for a total value of $4,160,183.06. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director Srikant M. Datar sold 350 shares of the stock in a transaction that occurred on Thursday, August 15th. The shares were sold at an average price of $215.00, for a total transaction of $75,250.00. Following the completion of the transaction, the director now directly owns 6,844 shares of the company’s stock, valued at $1,471,460. The disclosure for this sale can be found here. Insiders sold a total of 67,524 shares of company stock valued at $14,731,927 over the last ninety days. 7.20% of the stock is currently owned by insiders.
Shares of Stryker stock traded down $1.00 during midday trading on Friday, hitting $199.78. The company had a trading volume of 1,281,765 shares, compared to its average volume of 1,230,180. The stock has a market cap of $74.21 billion, a price-to-earnings ratio of 27.33, a PEG ratio of 2.43 and a beta of 0.80. The company has a quick ratio of 1.35, a current ratio of 2.18 and a debt-to-equity ratio of 0.64. The company has a fifty day simple moving average of $213.13 and a 200 day simple moving average of $205.63. Stryker Co. has a 12-month low of $144.75 and a 12-month high of $223.45.
Stryker (NYSE:SYK) last announced its quarterly earnings data on Tuesday, October 29th. The medical technology company reported $1.91 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $1.90 by $0.01. The firm had revenue of $3.59 billion during the quarter, compared to analyst estimates of $3.58 billion. Stryker had a net margin of 23.55% and a return on equity of 25.33%. Stryker’s revenue was up 10.6% on a year-over-year basis. During the same period last year, the firm posted $1.69 EPS. As a group, analysts expect that Stryker Co. will post 8.23 EPS for the current year.
Several brokerages have issued reports on SYK. Robert W. Baird increased their target price on shares of Stryker from $239.00 to $242.00 and gave the stock an “outperform” rating in a report on Wednesday, October 30th. Zacks Investment Research upgraded shares of Stryker from a “hold” rating to a “buy” rating and set a $225.00 target price on the stock in a report on Monday, July 29th. UBS Group increased their target price on shares of Stryker from $220.00 to $225.00 and gave the stock a “neutral” rating in a report on Wednesday, October 30th. Cantor Fitzgerald increased their target price on shares of Stryker from $190.00 to $230.00 and gave the stock a “neutral” rating in a report on Friday, July 26th. Finally, Royal Bank of Canada set a $220.00 target price on shares of Stryker and gave the stock a “buy” rating in a report on Friday, July 26th. Six analysts have rated the stock with a hold rating and eighteen have given a buy rating to the company’s stock. The company currently has a consensus rating of “Buy” and an average target price of $220.17.
Stryker Corporation operates as a medical technology company. The company operates through three segments: Orthopaedics, MedSurg, and Neurotechnology and Spine. The Orthopaedics segment provides implants for use in hip and knee joint replacements, and trauma and extremities surgeries. The MedSurg segment offers surgical equipment and surgical navigation systems, endoscopic and communications systems, patient handling, emergency medical equipment and intensive care disposable products, reprocessed and remanufactured medical devices, and other medical devices for use in various medical specialties.
Read More: Blue-Chip Stocks
Want to see what other hedge funds are holding SYK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Stryker Co. (NYSE:SYK).
Receive News & Ratings for Stryker Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Stryker and related companies with MarketBeat.com's FREE daily email newsletter.